• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Genmab to Participate in Chat at Citi Global Healthcare Conf

    GLOBENEWSWIRE

    Genmab Gets FDA Nod For Epkinly Combo In Follicular Lymphoma

    BUSINESSWIRE

    Genmab Sees Capital Boost From Employee Warrant Exercise

    GLOBENEWSWIRE

    Genmab Prices Notes Offering, Completes Loan Syndication

    GLOBENEWSWIRE

    Genmab Sheds Another Clinical ADC From $1.8B Profoundbio Buy

    FIERCE BIOTECH

    Genmab Announces Financial Results For The Nine Months Of 2025

    GLOBENEWSWIRE

    Genmab Presents Latest Blood Cancer Treatments at ASH 2025

    BUSINESSWIRE

    Genmab Initiates Tender Offer For Merus N.V. Shares

    GLOBENEWSWIRE

    Genmab Shows Rina-S Effectiveness In Advanced Endometrial Cancer

    GLOBENEWSWIRE

    Genmab Reports Darzalex Net Sales in Q3 2025

    GLOBENEWSWIRE

    Genmab Acquires Merus, Boosts Late-Stage Pipeline

    BUSINESSWIRE

    Genmab Grants Restricted Stock Units And Warrants To Employees

    GLOBENEWSWIRE

    Major Shareholder Announcement

    GLOBENEWSWIRE

    Genmab Discards ADC from $1.8 B ProfoundBio Buy

    FIERCE BIOTECH

    Genmab`s Capital Increase Due to Employee Warrant Exercise

    GLOBENEWSWIRE

    Genmab A/S Share Transactions by Managerial Staff and Associates

    GLOBENEWSWIRE

    Genmab Gets FDA Breakthrough Tag for Rina-S in Endometrial Cancer

    BUSINESSWIRE

    Genmab to Join Morgan Stanley Global Healthcare Conference

    GLOBENEWSWIRE

    Genmab Capital Increase Due to Employee Warrant Exercise

    GLOBENEWSWIRE

    Genmab Ph3 EPCORE FL-1 Trial Meets Endpoints in Lymphoma Patients

    PHARMAWEB

    Genmab Ph 3 EPCORE FL-1 Meets Endpoints in Follicular Lymphoma

    BUSINESSWIRE

    Genmab Ph 3 EPCORE FL-1 Meets Dual Primary Endpoints in Lymphoma

    GLOBENEWSWIRE

    Genmab Announces Financial Results for the First Half of 2025

    GLOBENEWSWIRE

    Genmab Reports Q2 2025 Net Sales of DARZALEX® (daratumumab)

    GLOBENEWSWIRE

    Genmab Announces Changes to its Executive Committee

    GLOBENEWSWIRE

    Completion of Share Buy-back Program

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Genmab A/s Managerial Employees and Associates` Share Transaction

    GLOBENEWSWIRE

    Genmab`s Epcoritamab Combo Shows High Response in DLBCL

    BUSINESSWIRE

    Genmab grants Restricted Stock Units and Warrants to Employees

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Genmab`s Rin-S Shows Promise in Endometrial Cancer Trial

    BUSINESSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Genmab to Join Chat at 46th Goldman Sachs Health Conference

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Endometrial Cancer Data on Genmab’s Elahere Rival Beat Forecast

    FIERCE BIOTECH

    Genmab to Present Late-Stage Oncology Data at 2025 ASCO Meeting

    BUSINESSWIRE

    Genmab to Join Fireside Chat at 2025 Jefferies Conference

    GLOBENEWSWIRE

    Genmab`s Capital Increases Due to Employee Warrant Exercise

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Genmab Announces Financial Results for the First Quarter of 2024

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Genmab reports Darzalex® Net Sales for Q1 2025

    GLOBENEWSWIRE

    Transactions in Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Genmab A/S Share Capital Reduction

    GLOBENEWSWIRE

    Transactions In Connection with Share Buy-back Program

    GLOBENEWSWIRE

    Genmab A/S Managerial Employees` Transactions with Shares

    GLOBENEWSWIRE

    Transactions in connection with share buy-back program

    GLOBENEWSWIRE

    TIVDAK® approved by European Commission for Cervical Cancer

    GLOBENEWSWIRE

    Tivdak approved by Japan Ministry for Advanced Cervical Cancer

    BUSINESSWIRE

    Genmab Announces Initiation of Share Buy-Back Program

    GLOBENEWSWIRE

    Genmab To Defend Against Trade Secret Claims By AbbVie

    GLOBENEWSWIRE

    Rinatabart Sesutecan Shows Antitumor Activity in Ovarian Cancer

    GLOBENEWSWIRE

    Rina-S: Shows Encouraging Antitumor Activity In Advanced Ovarian Cancer

    BUSINESSWIRE

    Passing of Genmab A/S Annual General Meeting

    GLOBENEWSWIRE

    Genmab A/S Board Grants Restricted Stock Units and Warrants

    GLOBENEWSWIRE

    Genmab A/S managerial employees and associates` share transaction

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.